Overall results for the international collaborative study
| Sample | Calculations from reported results | Relative to 15/174 |
| Percentage of labs with non-parallelism (n)* | ||
| 15/174 | 33% (39) | n/a |
| S1 | 38% (26) | 14% (28) |
| S2 | 17% (23) | 14% (28) |
| S3 | 22% (23) | 18% (28) |
| CLIFT endpoint titre GM†/%GCV‡ (n) | ||
| S1 | 268/153 (10) | 1.14/47 (10) |
| S2 | 266/143 (9) | 1.03/46 (9) |
| S3 | 1376/259 (10) | 5.84/88 (10) |
| Immunoassay potencies (IU/mL) GM/%GCV (n) | ||
| S1 | 200/123 (30) | 1.32/86 (24) |
| S2 | 199/184 (27) | 1.57/42 (20) |
| S3 | 1406/93 (27) | 8.2/117 (23) |
*(n): number of laboratories (when a laboratory performed more than one method, each method is treated as if performed by separate laboratories).
†GM: geometric mean (overall combined unweighted GM estimates).
‡%GCV: geometric coefficient of variation between laboratories.
CLIFT, Crithidia luciliae immunofluorescent test.